Jetstream Venture Fund Expands Healthtech Portfolio
Jetstream Venture Fund has made investments in healthtech companies ImageAiD and Moonrise Medical, both focused on AI-enabled vascular diagnostic platforms. These innovations aim to enhance the early detection and management of Peripheral Artery Disease (PAD), affecting over 200 million people worldwide. Jetstream leverages deep industry ties to back promising startups that streamline advanced diagnostics to improve clinical workflows.
SCOTTSDALE, Ariz., Aug. 27, 2026 /PRNewswire/ — Jetstream Venture Fund (Jetstream) announced its latest portfolio investments in healthtech pioneers ImageAiD and Moonrise Medical. Both companies are developing next-generation, AI-enabled vascular diagnostic platforms to transform the early detection and management of Peripheral Artery Disease (PAD), a condition affecting over 200 million people globally and 12 million in the U.S.
The transactions highlight Jetstream’s ability to originate high-conviction, early-stage deal flow directly through its leadership team’s lifelong operational, clinical, and healthcare founder network. While traditional retail platforms struggle to access specialized medical startups, Jetstream leverages these deep industry roots to back innovations that shift advanced diagnostic tools directly to the point of care:
- ImageAiD: Combines Mayo Clinic-validated research, a handheld Doppler device, and predictive AI software to detect PAD years before physical symptoms appear in primary care settings.
- Moonrise Medical: Automates complex Doppler ultrasound assessments and Pedal Acceleration Time (PAT) calculations, empowering front-line clinicians to evaluate vascular health accurately without requiring specialized sonographers.
“Vascular care today is far too reactive; patients are routinely diagnosed only after irreversible tissue damage has occurred,” said Mike Shufeldt, Portfolio Manager at Jetstream. “Our leadership team has spent decades on the front lines of clinical medicine, healthtech commercialization, and venture investing. That hands-on background allows us to evaluate complex medical platforms early and secure potentially high-value deal flow that standard venture networks miss. Both ImageAiD and Moonrise Medical exemplify our core thesis: leveraging automation and software to move sophisticated diagnostics upstream into everyday clinical workflows.”
By maintaining a $5,000 minimum initial investment and no carried interest, Jetstream democratizes access to institutional-quality opportunities alongside positions like SpaceX, Shield AI, and Hill Research.
Schedule a call to learn more about becoming an investor with Jetstream, or visit the website for more portfolio insights.
About Jetstream Venture Fund
Jetstream Venture Fund is an interval fund managed by Xcellerant Ventures and Sweater Industries LLC that provides access to early-stage, potentially high-growth private companies with lower minimums ($5,000) and no carried interest. For more information, visit www.jvf.vc.
Disclosure: Investors should carefully consider the investment objectives, risks, charges, and expenses of the Fund before investing. The prospectus contains this and other information and can be obtained by visiting https://www.jvf.vc. Please read the prospectus carefully before investing.
Media Contact: Dawson Fearnow | MMPR Marketing | dawson@mmprmarketing.com | 602-264-2655
View original content:https://www.prnewswire.com/news-releases/jetstream-venture-fund-expands-healthtech-portfolio-with-investments-in-imageaid-and-moonrise-medical-302861208.html
SOURCE Jetstream Venture Fund